NSPRNSPRHealthcare · Medical Devices

NSPR Stock Forecast: InspireMD, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.54
−12.90% on the day

The median 12-month analyst price target for InspireMD, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 73 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$33.6M
Ticker Nerd rank
73/ 100
Median analyst target
$3.00
Analysts covering
3
Revenue$1.8M−0.4% y/y
Operating income−$14.4M
Net income−$14.3M
Free cash flow−$11.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.6%
1M
+22.7%
YTD
−69.7%
1Y
−68.2%
From 52W high
−74.9%
From 52W low
+22.7%
$0.44
$2.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores InspireMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
73/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
95
Growth
93
Volatility
87
Accruals
74
Issuance
50
Value
30
Quality
15
Momentum
13

Revisions (95): Analysts have, on balance, been raising their forecasts.

Momentum (13): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NSPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NSPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26NSPRHigh $4.00Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$2.00
Low
$3.00
Median
$4.00
High
Recent analyst actionsNewest first

Of the 11 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
5 May 2026Piper SandlerReiteratesOverweight$4.00 → $3.00
12 May 2025Piper SandlerMaintainsOverweight—
11 Dec 2024Lake StreetInitiatesBuy—
17 Sept 2024Piper SandlerReiteratesOverweight$4.50
2 Nov 2023Piper SandlerMaintainsOverweight—
12 June 2023Piper SandlerInitiatesOverweight—
17 May 2023National Alliance SecuritiesMaintainsBuy—
31 Mar 2023Alliance Global PartnersMaintainsBuy—
16 Oct 2020Alliance Global PartnersInitiatesBuy$0.70
11 Mar 2020HC Wainwright & Co.ReiteratesBuy$5.00 → $2.00
29 Mar 2016Rodman & RenshawMaintainsBuy$4.00 → $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NSPR.

Market Radar

This page is one stock. Monday covers all of them.

NSPR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NSPR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, InspireMD, Inc. returned −68.2% against +6.9% for the S&P 500, dividends included.

NSPR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26NSPRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NSPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.2×

Cheaper than 34% of US stocks

Price / book
1.3×

Cheaper than 59% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
−43.7%

Higher than 2% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−115.4%

Higher than 12% of US stocks

Return on assets
−55.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • InspireMD, Inc. has a market value of $33.6M and an enterprise value of $11.7M.

  • Revenue in the twelve months to 30 June 2026: $10.8M. The latest quarter shrank 0.4% year on year.

  • Net income over the same four quarters: −$52.5M, a −484.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.64.

  • Free cash flow in the twelve months to 30 June 2026: −$42.5M.

  • Shares outstanding: 46.8M.

  • InspireMD, Inc. employs 127 people — $85K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NSPR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NSPRInspireMD, Inc.$33.6M73
NSYSNortech Systems, Inc.$29.4M82
XTNTXtant Medical Holdings, Inc.$29.5M51
QTIQT Imaging Holdings, Inc.$28.1M20
TELATELA Bio, Inc.$31.1M36
MYOMyomo, Inc.$32.1M62
MDAISpectral AI, Inc.$33.5M26

Take a look at NSPR’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own InspireMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NSPR

What is the NSPR stock price forecast for 2026-2027?

The median 12-month analyst price target for InspireMD, Inc. is $3, with estimates ranging from $2 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NSPR stock a buy right now?

Of the 3 analysts covering InspireMD, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InspireMD, Inc. 73 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NSPR?

As at 21 Nov 2026, InspireMD, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).

Will NSPR stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $3, and Ticker Nerd's factor model ranks InspireMD, Inc. 73 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NSPR stock forecast for 2030?

No analyst covering InspireMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NSPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $4 over the next 12 months.

How has NSPR stock performed over the past year?

InspireMD, Inc. returned -68.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InspireMD, Inc. do?

InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions. The company’s portfolio centers on its proprietary CGuard™ carotid stent platform and MicroNet™ mesh technology, which are designed to support embolic protection during and after stenting procedures.

Company

About InspireMD, Inc.

InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions. The company’s portfolio centers on its proprietary CGuard™ carotid stent platform and MicroNet™ mesh technology, which are designed to support embolic protection during and after stenting procedures. InspireMD’s current products include carotid embolic prevention and stent systems used in vascular and neurovascular interventions, with applications across stroke prevention and related artery treatment settings. The company serves physicians, hospitals, and healthcare providers in multiple international markets, including the United States and select regions in Europe, the Middle East, Latin America, and Asia Pacific. InspireMD plays a specialized role in the medical technology market by focusing on device-based solutions for complex carotid and coronary care.

CEO Mr. Marvin L. Slosman · 127 employees · United States · https://www.inspiremd.com